Sionna Therapeutics targets cystic fibrosis with novel CFTR/NBD1 stabilization; key 2026 readouts and cash runway to 2028.

Since Chile’s Economic and Environmental Crimes Act (Law No. 21.595) came into effect, amending Law No. 20.393 on the criminal liability of ...

AnnieMac CEO Joe Panebianco has navigated a broad range of risks, from cash buyer competition to shifts in the market's loan ...

Bocunebart's PACAP-targeting mechanism positions it as a potential first-in-class therapy in a thin pipeline of novel ...

Annual Awards Program Recognizes Innovation in the Global Supply Chain Technology and Logistics Industry LOS ANGELES, July 01, 2026 (GLOBE NEWSWIRE) -- SupplyTech Breakthrough, a leading independent ...

Scientists say they have built a cell from scratch for the first time that can feed, grow and replicate like a natural cell.

The fix was on my desk the whole time.

Forward Industries must address its mandate, corporate governance, capital allocation discipline, related-party structure, ...

Reasons to be Cheerful reports that cycling improves focus in kids, especially those with ADHD, as seen in Spooner Middle ...

Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for 2L+ R/M HNSCC patients treated with MICVO at or below a dose cap ...

LLVM powers the core development tools, operating systems, and most applications at Apple Computer, where it long ago ...

Taysha Gene Therapies (TSHA) remains a Buy on strong TSHA-102 Rett data, FDA-aligned pivotal path, and cash to 2028—read the ...